Optical Coherence Tomography Guided Percutaneous Coronary Intervention for Drug-eluting In-stent Restenosis
Not Applicable
- Conditions
- In-stent RestenosisCHD - Coronary Heart DiseasePercutaneous Coronary Intervention
- Interventions
- Procedure: Percutaneous Coronary Intervention under AngiographyProcedure: Percutaneous Coronary Intervention under OCT
- Registration Number
- NCT03809754
- Lead Sponsor
- Chinese PLA General Hospital
- Brief Summary
This study is a prospective, registry trial aimed to compare the clinical and angiographic outcomes of OCT-guided and angiography-guided PCI in patients with coronary DES-ISR.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 240
Inclusion Criteria
- Age 18 years or older
- Patients with angina or evidence of myocardial ischaemia
- Patients with restenotic lesions in a previously DES area of a coronary artery
- Patients suitable to receive any types of percutaneous coronary intervention (including balloon angioplasty and stent implantation)
- The stent diameter of DES-ISR is 2.5mm to 4.0mm
- Target lesion length < 30mm
- Target lesion stenosis ≥ 70% diameter stenosis on visual assessment, or ≥ 50% diameter stenosis and with evidence of myocardial ischaemia ischemic
Exclusion Criteria
- Patients with acute myocardial infarction with 1 week
- Patients with evidence of extensive thrombosis in the target vessel
- Patients with left main coronary artery disease
- Patients with cardiogenic shock, left ventricular ejection fraction < 40%,significant renal dysfunction and severe heart valve disease
- Patients who had cerebral stroke within 6 months before PCI
- Patients with a life expectancy < 1 year
- Patients not able to adhere to follow-up visits
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Angiography-guided PCI Percutaneous Coronary Intervention under Angiography - OCT-guided PCI Percutaneous Coronary Intervention under OCT -
- Primary Outcome Measures
Name Time Method In-segment late loss at 9 months follow-up 9 months
- Secondary Outcome Measures
Name Time Method Rate of 9-month binary restenosis 9 months Rate of myocardial infarction 12 months Rates of acute success 1 month Rate of major adverse cardiovascular events 12 months Number of participants with all-cause death 12 months Number of Participants with target lesion failure (TLF) 12 months
Trial Locations
- Locations (1)
Yundai Chen
🇨🇳Beijing, China